Suchergebnisse - "Liao, Aijun"

PubPharm (69)

1

The efficacy and safety of fexuprazan in treating erosive esophagitis : a phase III, randomized, double-blind, multicenter study

enthalten in: Journal of gastroenterology and hepatology | 2024

von Zhuang, Q. | Liao, A. | He, Q. | +36

2

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis

enthalten in: Journal of experimental & clinical cancer research : CR | 2024

von Wang, X. | Shi, Y. | Shi, H. | +6

3

The efficacy and safety of fexuprazan in treating erosive esophagitis : a phase III, randomized, double‐blind, multicenter study

enthalten in: Journal of Gastroenterology and Hepatology | 2024

von Zhuang, Q. | Liao, A. | He, Q. | +36

4

Application of pyroptosis score in the treatment and prognosis evaluation of gastric cancer

enthalten in: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences | 2023

von Li, L. | Liao, A.

5

Patient Journey Toward a Diagnosis of Light Chain Amyloidosis in a National Sample : Cross-Sectional Web-Based Study

enthalten in: JMIR formative research | 2023

von Dou, X. | Liu, Y. | Liao, A. | +6

6

Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma : a retrospective multicenter study from China

enthalten in: BMC cancer | 2023

von Sun, H. | Liu, A. | Liu, L. | +17

7

SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation

enthalten in: The Journal of clinical investigation | 2023

von Cusan, M. | Shen, H. | Zhang, B. | +16

8

METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL

enthalten in: Blood cancer discovery | 2023

von Wu, Y. | Jin, M. | Fernandez, M. | +18

CommentIn: Blood Cancer Discov. 2023 May 1;4(3):176-179. - PMID 37067902

9

RASSF1A inhibits epithelial-mesenchymal transition of gastric cancer cells by downregulating P-JNK

enthalten in: Cell biology international | 2023

von Bin, Y. | Deng, W. | Hu, H. | +6

10

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma : a real-world multi-centered study in China

enthalten in: Frontiers in oncology | 2023

von Zhuang, Z. | Tian, Y. | Shi, L. | +18

1
2
3
4
5
6
7
Nächster »
[7]